Loading
Metastasis and Carcinoma Case Studies / Gastric Cancer Management and Outcomes · Journal article
Frontiers in Oncology · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a narrative review that synthesizes case reports and existing literature on gastric metastasis from colorectal cancer, a rare clinical entity characterized by diagnostic and therapeutic challenges. The source confirms median age at onset ~65 years, median survival ~12 months, and diagnostic reliance on immunohistochemical markers (CK7−/CK20+/CDX2+), but acknowledges lack of large-scale epidemiological data and high-level evidence-based guidance for treatment.
Narrative review. Case reports and published literature on gastric metastasis from colorectal cancer; no original prospective or retrospective cohort.
Median age at onset approximately 65 years among available case reports Left-sided colon is the most common primary site in gastric metastases from CRC Interval between primary tumor diagnosis and gastric metastasis ranges from 6 months to 10 years
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should maintain high suspicion for gastric metastasis in CRC patients with gastric symptoms, especially to avoid misdiagnosis as primary gastric cancer. Current evidence supports use of metastatic CRC chemotherapy regimens (FOLFOX, FOLFIRI with targeted therapy) and selective surgical resection, but prognosis remains poor and treatment guidance remains empirical rather than evidence-based.
A narrative review synthesizing case reports and empirical estimates of a rare condition with acknowledged lack of large-scale epidemiological data, offering descriptive and mechanistic insight but no original empirical evidence or comparative outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should maintain high suspicion for gastric metastasis in CRC patients with gastric symptoms, especially to avoid misdiagnosis as primary gastric cancer. Current evidence supports use of metastatic CRC chemotherapy regimens (FOLFOX, FOLFIRI with targeted therapy) and selective surgical resection, but prognosis remains poor and treatment guidance remains empirical rather than evidence-based.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Colorectal cancer (CRC) is one of the most common and deadly malignancies worldwide, with metastasis being its most lethal feature. Although the liver and lungs are well-recognized sites of metastasis, gastric involvement as a target organ is extremely rare. The exact incidence remains unclear due to the lack of large-scale epidemiological data, and existing literature consists mainly of case reports and empirical risk estimates. This rarity, combined with the frequent misdiagnosis of gastric metastases as primary gastric cancer in clinical practice, makes gastric metastasis from CRC a unique clinical entity characterized by diagnostic challenges and therapeutic difficulties. Analysis of available case reports indicates that the median age at onset is approximately 65 years, with the left-sided colon being the most common primary site. The interval between diagnosis of the primary tumor and development of gastric metastasis ranges from 6 months to 10 years. Diagnosis primarily relies on a combination of immunohistochemical markers—CK7−/CK20+/CDX2+—while the emerging marker SATB2 further enhances diagnostic specificity. Currently, there is limited high-level evidence-based guidance for treatment; systemic chemotherapy regimens used for metastatic CRC—such as FOLFOX or FOLFIRI combined with targeted therapy—are typically employed. Surgical resection may be considered for isolated, resectable gastric metastases, but overall prognosis remains poor, with a median survival of approximately 12 months. This review comprehensively summarizes the epidemiological characteristics, molecular mechanisms, clinicopathological diagnosis, routes and mechanisms of metastasis, clinical manifestations, diagnostic strategies, differential diagnosis, treatment options, and prognostic factors associated with gastric metastasis from CRC, aiming to provide clinicians with a comprehensive understanding of this rare condition and to serve as a reference for future research and clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.